Clinical trial
A Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of the Efficacy, Tolerability, and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Amoxicillin/Clavulanate for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women
NCT05584657 is registered in ClinicalTrials.gov with Iterum Therapeutics, International Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of the Efficacy, Tolerability, and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Amoxicillin/Clavulanate for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women
- Lead sponsor
- Iterum Therapeutics, International Limited
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 18, 2022
- Completion date
- November 21, 2023
- Enrollment
- 2,229 (actual)
- Sites
- 167
Conditions
As the registry lists them; a condition with its own page is linked.